Eating foods at breakfast that have a low glycemic index may help prevent a spike in blood sugar throughout the morning and after the next meal of the day, researchers said at the Institute of Food Technologists' Wellness 12 meeting. These breakfast foods also can increase feelings of satiety and fullness and may make people less likely to overeat throughout the day, acdcording to presentations Wednesday by Kantha Shelke, Ph.D., principal, Corvus Blue LLC, and Richard Mattes, M.P.H., R.D., distinguished professor of foods and nutrition at Purdue University. The glycemic index ranks foods on the extent to which they raise blood sugar levels after eating. Foods with a high index are rapidly digested and result in high fluctuations in blood sugar levels. Foods with a low glycemic index produce gradual rises in blood sugar and insulin levels and are considered healthier, especially for people with diabetes.
According to a study published Online First by Archives of Ophthalmology, bevacizumab appears to be more effective at treating diabetic macular edema (swelling of the retina) than macular laser therapy. The researchers of the randomized controlled trial found that among participants with persistent clinically significant diabetic macular edema (CSME), bevacizumab showed to be effective at 12 months and was maintained through 24 months. For the past 30 years, Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular laser therapy (MLT) has been the leading treatment for individuals suffering from CSME. Although MLT lowers the risk of moderate visual loss, improved treatments have been sought as visual acuity only improves in less than 3% of patients (a 15-letter gain at 3 years).
Lowering glucose levels for people with diabetes is normally critical to improving health outcomes. But for those with heart failure, that might not always be the case, say UCLA researchers. A new study found that for advanced heart failure patients with diabetes, having higher blood glucose levels may actually help improve survival rates. Currently published online in the American Journal of Cardiology, UCLA researchers compared levels of a marker used to track glucose levels called glycosylated hemoglobin in advanced heart failure patients with and without diabetes. The marker is gauged through a simple blood test. The study assessed the relationship between levels of the marker and mortality outcomes. Researchers found that for heart failure patients with diabetes, for every unit increase in the marker, there was a 15 percent decrease in mortality.
A study published in Cell Metabolism reports that scientists at the Dana-Farber Cancer Institute have discovered why some patients who receive rapamycin, an immuno-suppressant that also has anti-cancer activity, and may even slow ageing, have developed symptoms similar to diabetes. Rapamycin, which is commonly administered to prevent organ rejection, is currently undergoing clinical trials as a cancer treatment. However, about 15% of patients have developed insulin resistance and glucose intolerance after taking the drug. Until now, scientists have been unable to identify the reason. According to the researchers, normal mice that were given rapamycin had a higher risk of experiencing difficulties in regulating their blood sugar. This was due to a drop in insulin signaling that was triggered by activity of a protein called Yin Yang 1 (YY1).
Molecular Switch That Controls Liver Glucose Production May Lead To Treatment For Insulin-Resistant Type II Diabetes
In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver's production of glucose - the simple sugar that is the source of energy in human cells and the central player in diabetes. In a paper published in Nature, the scientists say that controlling the activity of these two molecules -- which work together to allow more or less glucose production - could potentially offer a new way to lower blood sugar to treat insulin-resistant type II diabetes. They showed, through an experimental technique, that this was possible in diabetic mice. "If you control these switches, you can control the production of glucose, which is really at the heart of the problem of type 2 diabetes, " says Professor Marc Montminy, head of Salk's Clayton Foundation Laboratories for Peptide Biology.